Pfizer Cash on Hand 2012-2025 | PFE
Pfizer cash on hand from 2012 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Pfizer cash on hand for the quarter ending September 30, 2025 was $14.984B, a 50.56% increase year-over-year.
- Pfizer cash on hand for 2024 was $20.477B, a 61.36% increase from 2023.
- Pfizer cash on hand for 2023 was $12.69B, a 44.18% decline from 2022.
- Pfizer cash on hand for 2022 was $22.732B, a 26.83% decline from 2021.
|
Pfizer Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2024 | $20,477 |
| 2023 | $12,690 |
| 2022 | $22,732 |
| 2021 | $31,069 |
| 2020 | $12,223 |
| 2019 | $9,646 |
| 2018 | $18,833 |
| 2017 | $19,992 |
| 2016 | $17,850 |
| 2015 | $23,290 |
| 2014 | $36,122 |
| 2013 | $32,408 |
| 2012 | $32,399 |
| 2011 | $26,452 |
|
Pfizer Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2025-09-30 | $14,984 |
| 2025-06-30 | $13,249 |
| 2025-03-31 | $17,317 |
| 2024-12-31 | $20,477 |
| 2024-09-30 | $9,952 |
| 2024-06-30 | $7,100 |
| 2024-03-31 | $11,928 |
| 2023-12-31 | $12,690 |
| 2023-09-30 | $44,181 |
| 2023-06-30 | $44,785 |
| 2023-03-31 | $19,972 |
| 2022-12-31 | $22,732 |
| 2022-09-30 | $36,123 |
| 2022-06-30 | $33,304 |
| 2022-03-31 | $23,897 |
| 2021-12-31 | $31,069 |
| 2021-09-30 | $29,696 |
| 2021-06-30 | $21,700 |
| 2021-03-31 | $13,667 |
| 2020-12-31 | $12,223 |
| 2020-09-30 | $21,912 |
| 2020-06-30 | $22,794 |
| 2020-03-31 | $10,350 |
| 2019-12-31 | $9,646 |
| 2019-09-30 | $9,087 |
| 2019-06-30 | $12,912 |
| 2019-03-31 | $11,619 |
| 2018-12-31 | $18,833 |
| 2018-09-30 | $17,239 |
| 2018-06-30 | $13,431 |
| 2018-03-31 | $11,421 |
| 2017-12-31 | $19,992 |
| 2017-09-30 | $16,925 |
| 2017-06-30 | $14,333 |
| 2017-03-31 | $14,560 |
| 2016-12-31 | $17,850 |
| 2016-09-30 | $14,371 |
| 2016-06-30 | $20,942 |
| 2016-03-31 | $19,443 |
| 2015-12-31 | $23,290 |
| 2015-09-30 | $20,658 |
| 2015-06-30 | $30,256 |
| 2015-03-31 | $27,708 |
| 2014-12-31 | $36,122 |
| 2014-09-30 | $33,446 |
| 2014-06-30 | $34,054 |
| 2014-03-31 | $33,881 |
| 2013-12-31 | $32,408 |
| 2013-09-30 | $33,679 |
| 2013-06-30 | $33,711 |
| 2013-03-31 | $35,346 |
| 2012-12-31 | $32,399 |
| 2012-09-30 | $22,968 |
| 2012-06-30 | $24,306 |
| 2012-03-31 | $23,972 |
| 2011-12-31 | $26,452 |
| 2011-09-30 | $28,963 |
| 2011-06-30 | $25,484 |
| 2011-03-31 | $24,009 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $147.203B | $63.627B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $976.553B | 46.97 |
| Johnson & Johnson (JNJ) | United States | $529.009B | 21.15 |
| AbbVie (ABBV) | United States | $383.081B | 22.94 |
| Roche Holding AG (RHHBY) | Switzerland | $344.774B | 0.00 |
| Novartis AG (NVS) | Switzerland | $302.393B | 16.03 |
| Merck (MRK) | United States | $275.430B | 12.83 |
| Novo Nordisk (NVO) | Denmark | $255.041B | 14.95 |
| Sanofi (SNY) | France | $115.780B | 11.20 |
| Bayer (BAYRY) | Germany | $47.824B | 8.39 |
| Innoviva (INVA) | United States | $1.477B | 7.40 |